Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 12:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Intravitreal Aflibercept Injection (IAI) Clear all
Terminated Phase 2 Interventional Results available

Study of Intravitreal REGN2176-3 in Participants With Neovascular ("Wet") Age-Related Macular Degeneration (AMD)

NCT02418754
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
REGN2176-3, Intravitreal Aflibercept Injection (IAI)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
75
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 72 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2020 · Synced Sep 25, 2026, 12:26 AM EDT
Completed Phase 1 Interventional

Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome

NCT01578720
View directory record Official record
Conditions
Choroidal Neovascularization, Presumed Ocular Histoplasmosis
Interventions
EYLEA (Aflibercept) intravitreal injection
Drug
Lead sponsor
Retina Research Institute, LLC
Other
Eligibility
21 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 25, 2026, 12:26 AM EDT
Completed Phase 3 Interventional Results available

Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema

NCT01363440
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321), Macular Laser Photocoagulation
Drug · Procedure
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
51
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 48 more
Source: ClinicalTrials.gov public record
Updated May 29, 2016 · Synced Sep 25, 2026, 12:26 AM EDT
Completed Phase 2 Interventional Results available

DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact

NCT00789477
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Laser Photocoagulation, Intravitreal Aflibercept Injection
Procedure · Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
42
States / cities
Artesia, California • Beverly Hills, California • Mountain View, California + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Sep 25, 2026, 12:26 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy (RIVAL Trial)

NCT02092532
View directory record Official record
Conditions
Neovascular Polypoidal Choroidal Vasculopathy
Interventions
Rescue Intravitreal Aflibercept Injection, Rescue Therapy with PDT, Laser or Intravitreal Steroids
Drug · Procedure
Lead sponsor
Southeast Retina Center, Georgia
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Sep 25, 2026, 12:26 AM EDT
Not listed Phase 1Phase 2 Interventional

Intense Treatment Regimen With Intravitreal Aflibercept Injection

NCT03594461
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
Aflibercept Injection
Drug
Lead sponsor
Vitreous -Retina- Macula Consultants of New York
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Sep 25, 2026, 12:26 AM EDT
Completed Phase 2Phase 3 Interventional

Treatment With Intravitreal Aflibercept Injection For Proliferative Diabetic Retinopathy, The A.C.T Study

NCT01813773
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
Intravitreal Aflibercept Injection (IAI)
Drug
Lead sponsor
Ophthalmic Consultants of Long Island
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Lynbrook, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2016 · Synced Sep 25, 2026, 12:26 AM EDT
Withdrawn Phase 4 Interventional

Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal Ranibizumab

NCT03059277
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Intravitreal Aflibercept
Drug
Lead sponsor
Southeast Clinical Research Associates, LLC
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Charlotte, North Carolina • Statesville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Sep 25, 2026, 12:26 AM EDT
Not listed Phase 2 Interventional

Intravitreal Aflibercept Injection for Radiation Retinopathy Trial

NCT03085784
View directory record Official record
Conditions
Radiation Retinopathy
Interventions
Aflibercept
Drug
Lead sponsor
Amy C Schefler, MD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Houston, Texas • Katy, Texas • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Sep 25, 2026, 12:26 AM EDT
Completed Phase 2 Interventional Results available

IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD

NCT02462889
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Intravitreal aflibercept injection, Placebo
Drug
Lead sponsor
Jeffrey S Heier
Other
Eligibility
Not listed
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
4
States / cities
Beverly Hills, California • Boston, Massachusetts • Edison, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 25, 2026, 12:26 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe

NCT03767738
View directory record Official record
Conditions
Chorioretinal Vascular Disease
Interventions
Intravitreal Aflibercept Injection (IAI)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Houston, Texas • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2021 · Synced Sep 25, 2026, 12:26 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab

NCT03340610
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Alflibercept
Drug
Lead sponsor
Southeast Retina Center, Georgia
Other
Eligibility
18 Years to 95 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated May 23, 2019 · Synced Sep 25, 2026, 12:26 AM EDT
Not listed Phase 4 Interventional

Treat and Extend Therapy Study Using Intravitreal Aflibercept for Patients Exited From Protocol VGFT-OD 0910

NCT01961414
View directory record Official record
Conditions
Exudative Age-related Macular Degeneration
Interventions
Aflibercept
Drug
Lead sponsor
Palmetto Retina Center, LLC
Other
Eligibility
Not listed
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
6
States / cities
Augusta, Georgia • Lincoln, Nebraska • West Columbia, South Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Sep 25, 2026, 12:26 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Endolaserless Vitrectomy With Intravitreal IAI for PDR-Related VH

NCT02976012
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
Aflibercept, Endolaserless Vitrectomy
Drug · Procedure
Lead sponsor
Southeast Retina Center, Georgia
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Sep 25, 2026, 12:26 AM EDT
Completed Phase 4 Interventional Results available

The IAI-OCTA Study; a Study of OCT-Angiography Analysis Efficacy

NCT03022292
View directory record Official record
Conditions
Wet Macular Degeneration
Interventions
Aflibercept Ophthalmic, optovue angiovue
Drug · Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
50 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Sep 25, 2026, 12:26 AM EDT
Completed Phase 4 Interventional

NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions

NCT01870427
View directory record Official record
Conditions
Macular Edema With Central Retinal Vein Occlusions
Interventions
Aflibercept (2.0 mg)
Drug
Lead sponsor
Northern California Retina Vitreous Associates
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Sep 25, 2026, 12:26 AM EDT
Completed Phase 2 Interventional Results available

Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema

NCT02712008
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
REGN910-3, Intravitreal Aflibercept Injection (IAI)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
51
States / cities
Mesa, Arizona • Tucson, Arizona • Arcadia, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Sep 25, 2026, 12:26 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Retinal Detachment Repair

NCT04580147
View directory record Official record
Conditions
Retinal Detachment With Multiple Breaks, Unspecified Eye, Proliferative Vitreoretinopathy
Interventions
Intravitreal aflibercept injection, Sham control
Drug · Other
Lead sponsor
M. Ali Khan, MD
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2022 · Synced Sep 25, 2026, 12:26 AM EDT
Completed Phase 3 Interventional Results available

Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)

NCT00964795
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
Intravitreal Aflibercept Injection 2mg
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
115
States / cities
Birmingham (2 Locations), Alabama • Phoenix (2 Locations), Arizona • Tucson (2 Locations), Arizona + 112 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2015 · Synced Sep 25, 2026, 12:26 AM EDT
Completed Phase 1Phase 2 Interventional

Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion

NCT01724554
View directory record Official record
Conditions
Central Retinal Vein Occlusion, Proliferative Diabetic Retinopathy
Interventions
Intravitreal Aflibercept Injection
Drug
Lead sponsor
Ophthalmic Consultants of Boston
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Sep 25, 2026, 12:26 AM EDT
Completed Phase 2 Interventional Results available

Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection

NCT02713204
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
REGN910-3, Intravitreal Aflibercept Injection (IAI)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
87
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Sep 25, 2026, 12:26 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration

NCT04126317
View directory record Official record
Conditions
Neovascular (Wet) Age-Related Macular Degeneration
Interventions
aflibercept, High-dose aflibercept
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
45
States / cities
Phoenix, Arizona • Sun City, Arizona • Encino, California + 42 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 25, 2026, 12:26 AM EDT
Completed Phase 3 Interventional Results available

Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)

NCT02718326
View directory record Official record
Conditions
Nonproliferative Diabetic Retinopathy
Interventions
Intravitreal aflibercept injection [IAI], Sham
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
71
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 63 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Sep 25, 2026, 12:26 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)

NCT01521559
View directory record Official record
Conditions
Branch Retinal Vein Occlusion
Interventions
Macular Laser Photocoagulation, Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
Procedure · Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
45
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2014 · Synced Sep 25, 2026, 12:26 AM EDT